New York State Teachers Retirement System Purchases 230 Shares of Jazz Pharmaceuticals PLC $JAZZ

New York State Teachers Retirement System grew its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 0.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 44,077 shares of the specialty pharmaceutical company’s stock after purchasing an additional 230 shares during the quarter. New York State Teachers Retirement System owned about 0.07% of Jazz Pharmaceuticals worth $4,677,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in JAZZ. Nuveen LLC bought a new position in Jazz Pharmaceuticals during the 1st quarter worth approximately $62,362,000. Fuller & Thaler Asset Management Inc. raised its holdings in Jazz Pharmaceuticals by 41.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after purchasing an additional 391,660 shares during the last quarter. Perpetual Ltd raised its holdings in Jazz Pharmaceuticals by 60.2% during the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company’s stock worth $118,212,000 after purchasing an additional 357,784 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Jazz Pharmaceuticals by 14.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after purchasing an additional 293,360 shares during the last quarter. Finally, Boston Trust Walden Corp increased its stake in shares of Jazz Pharmaceuticals by 129.1% in the 2nd quarter. Boston Trust Walden Corp now owns 407,897 shares of the specialty pharmaceutical company’s stock valued at $43,286,000 after acquiring an additional 229,885 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $134.85 on Tuesday. The company has a fifty day simple moving average of $128.69 and a 200 day simple moving average of $116.14. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The company has a market cap of $8.18 billion, a P/E ratio of -20.04, a PEG ratio of 8.35 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the business posted $5.30 EPS. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on JAZZ shares. The Goldman Sachs Group lifted their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research note on Friday, August 29th. Truist Financial lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Royal Bank Of Canada lifted their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 8th. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $179.80.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $140.00, for a total value of $490,000.00. Following the completion of the sale, the director owned 408,826 shares of the company’s stock, valued at approximately $57,235,640. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 11,500 shares of company stock valued at $1,525,280. Company insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.